絞り込み

17305

広告

「"Verbeek MM "[Author]」の検索結果

255件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Downregulation of synapse-associated protein expression and loss of homeostatic microglial control in cerebrospinal fluid of infectious patients with delirium and patients with Alzheimer's disease.

Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy.

Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagen-encapsulated human umbilical cord mesenchymal stem cells.

Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH) deficiencies.

Confirmation of neurometabolic diagnoses using age-dependent cerebrospinal fluid metabolomic profiles.

CSF α-synuclein correlates with CSF neurogranin in late-life depression.

CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD.

Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42.

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.

Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy.

Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology.

Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization.

The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Serum NFL discriminates Parkinson disease from atypical parkinsonisms.

Alpha-synuclein RT-QuIC in the CSF of uncertain cases of parkinsonism.

Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public.

Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls.

C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります